Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Marstacimab prophylaxis versus standard treatment in severe hemophilia A or B
2018-003660-31Phase 3Terminated
- Sponsor
- Pfizer
- Start
- Nov 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of marstacimab in hemophilia A and hemophilia B (HB) (2 arms), sponsored by Pfizer. Primary endpoint: Primary Efficacy Endpoint. Started Nov 2019; status: terminated.
02
Drugs
marstacimab
03
Conditions
hemophilia Ahemophilia B (HB)
Beyond the preview
Go deeper on 2018-003660-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003660-31.